Komisi Pemberantasan Korupsi (KPK) berhasil mengamankan barang bukti berupa uang bernilai ratusan juta sebagai barang bukti hasil kejahatan Romahurmuziy.
Meski belum diungkapkan secara gamblang soal kisaran uang yang diterima Rommy, namun KPK menyatakan bahwa jumlahnya memang di luar ekspektasi.
Terlebih, KPK sebelumnya mengungkap bahwa transaksi penerimaan suap yang melibatkan Rommy justru bukan kali pertama terjadi.
"Untuk uang yang diamankan sekitar seratusan juta. Ini di luar dugaan penerimaan sebelumnya," ujar Jubir KPK, Febri Dianysah dalam pesan singkatnya, Sabtu (16/3/2019) dini hari.
Diketahui, Rommy selaku ketua umum PPP dan juga seorang anggota DPR RI Komisi IV itu baru saja diamankan bersama Ketua Kanwil Kemenag Jatim, Haris Hasanudin sempat bermasalah ketika Komisi Aparatur Sipil Negara (KASN) merekomendasikan pembatalan pencalonannya dalam seleksi Kepala Kemenag Jatim.
Saat dikonfirmasi akan hal itu, Febri mengaju masih enggan membeberkan lebih lanjut, karena masih ada rangkaian pemeriksaan yang dilakukan tim penyidik hingga malam ini.
"Sabtu ini akan diumumkan hasil kegiatan tangkap tangan kemarin. Dari rangkaian fakta-fakta tersebut sudah terang dugaan tindak pidana korupsi. Namun selengkapnya akan diuraikan saat konferensi pers," kata Febri.
Cutaneous T-Cell Lymphoma
One of the most common forms of T-cell lymphoma is cutaneous T-cell lymphoma
(CTCL), a general term for T-cell lymphomas that involve the skin. CTCL can
also involve the blood, lymph nodes, and
other internal organs.
Symptoms can include dry skin, itching
(which can be severe), a red rash, and enlarged lymph nodes.
The disease affects men more often than women and usually occurs in men in
their 40s, 50s, and 60s.
Most patients with CTCL experience only
skin symptoms. Some patients with early stage CTCL
might not progress to later stages at all, while others might progress rapidly
with the cancer spreading to lymph nodes and/or internal
organs.
Subtypes of CTCL
CTCL describes many different disorders with various symptoms, outcomes, and
treatment considerations:
·
Mycosis Fungoides (MF): the most common type
of CTCL, accounting for approximately one-half of all CTCLs. MF can look
different in each patient, with skin symptoms that can appear as patches,
plaques, or tumors.
·
Sézary Syndrome: characterized by the presence of
lymphoma cells in the blood, patients with Sézary Syndrome often present with
extensive thin, red, itchy rashes that typically appear on the skin.
Cutaneous T-Cell Lymphoma: Treatment Options
Many factors are considered to identify the most appropriate treatment for
each patient, including the extent of skin involvement, the type of skin
lesion, and whether the cancer has
spread to the lymph nodes or other internal
organs.
For mycosis fungoides, treatment is either directed at the skin or the
entire body (systemic). Many patients live normal lives while they treat their
disease, and some are able to remain in remission for
long periods of time.
Since Sézary syndrome is systemic, one in which both blood and skin
involvement is noted, it is usually not treated with skin-directed therapies
alone. Treatments may be prescribed alone or in combination to achieve the best
long-term benefit.
·
Skin-Directed Therapies are generally used
for earlier stage disease and are
typically useful for patches and limited plaques.
o
Topical treatments such as corticosteroids, retinoids, imiquimod, or chemotherapy. The following topical treaments
have been approved by the U.S. Food and Drug Administration (FDA):
§
Bexarotene gel (Targretin)
§
Mechlorethamine gel (Valchor)
o
Local radiation
o
Ultraviolet light
·
Systemic Treatment may be used in more advanced stage
disease and in those with earlier stage disease in whom skin-directed therapies
did not help, were not tolerated, or are not available. Systemic treatments
include extracorporeal photopheresis (ECP) and/or single-agent or combination chemotherapy regimens, which may
include:
o
Acitretin (Soriatane)
o
Bexarotene capsules (Targretin)
o
Interferons (alpha or gamma)
o
Methotrexate tablets (Trexall)
o
Romidepsin (Istodax)
o
Vorinostat (Zolinza)
